CLAIM CARD
Quantitative findings from the observational data show a strong association between medication non-adherence and adverse outcomes. This suggests that consistent use of guideline-directed therapy, which often incorporates ARBs, is critical for survival benefits. However, the specific contribution of ARBs cannot be disentangled from the multi-drug regimens studied (Murray-Thomas 2025). The Wang 2026 meta-analysis reports that SGLT2 inhibitors, a drug class often used alongside ARBs, significantly reduced cardiovascular death compared to placebo, but ARB-specific mortality effects within this comparison were not separately quantified in the provided excerpts (Wang 2026).
Evidence grade: exploratory
Contradiction status: none
Publication: edeb045d-18ed-49dc-95b6-57f76783ce2b
Provenance: Derivation Web chain
Citation Support
source_1Solomon 2026source_2Din 2026source_3Li 2025source_4Mei 2025source_5Chung 2024